Fourteen years after AstraZeneca’s blood thinner Brilinta reached the market and now faces generic competition, the data that ...

Ratio Therapeutics and Ionetix have inked separate deals to boost production of the much-needed radioisotope actinium-225, ...

Roche has demonstrated the power of combining two of oncology's hottest modalities—bispecifics and antibody-drug conjugates ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

Life sciences commercial teams are drowning in data complexity. | ciATHENA eliminates the traditional barriers between ...

As the saying goes, “If you don’t laugh, you’ll cry.” Biogen and ad agency 21Grams took that mantra to heart with their Gold ...

In a first for the bloc, Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing ...

AstraZeneca has penned a drug discovery pact focused on chronic diseases with China's CSPC Pharma. The FDA has halted new trials that export U.S. individuals' living cells to China. | AstraZeneca has ...

In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...